A significant problem faced in oncology is the lack of chemotherapeutic agents that are tumor site-specific, resulting in reduced therapeutic efficacy and unintended infliction of harm to surrounding healthy tissues and cells that often lead to serious side effects. Current strategies being explored to circumvent this issue aim to refine delivery of chemotherapeutic agents specifically to tumor sites, which may be achieved via conjugation of these agents to biomarker-specific ligands. This forms the foundation of ligand-targeted drug delivery. Among different breast cancers, treatment of the triple-negative breast cancer (TNBC) subtype has been particularly challenging, largely due to the absence of a well-defined biomarker to exploit for targeted drug delivery. This has substantially limited the number of effective TNBC treatment options, funneling down primarily to conventional chemotherapy, the long-standing standard of care. The scope of this dissertation covers the peptide–drug conjugate (PDC) therapeutic modality. The findings herein delineate novel ligands, targets, and PDCs for effectively targeting TNBC.
","abstract_html":"<p>A significant problem faced in oncology is the lack of chemotherapeutic agents that are tumor site-specific, resulting in reduced therapeutic efficacy and unintended infliction of harm to surrounding healthy tissues and cells that often lead to serious side effects. Current strategies being explored to circumvent this issue aim to refine delivery of chemotherapeutic agents specifically to tumor sites, which may be achieved via conjugation of these agents to biomarker-specific ligands. This forms the foundation of ligand-targeted drug delivery. Among different breast cancers, treatment of the triple-negative breast cancer (TNBC) subtype has been particularly challenging, largely due to the absence of a well-defined biomarker to exploit for targeted drug delivery. This has substantially limited the number of effective TNBC treatment options, funneling down primarily to conventional chemotherapy, the long-standing standard of care. The scope of this dissertation covers the peptide–drug conjugate (PDC) therapeutic modality. The findings herein delineate novel ligands, targets, and PDCs for effectively targeting TNBC.</p>","abstract_has_math":false,"creators":["Yao, Shih-Jing (Jane)"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation","degree_discipline":"Pharmaceutical Sciences","degree_department":null,"school":null,"contributors":["Kamaljit Kaur","Jennifer Totonchy","Hamidreza Montazeri Aliabadi","Madeline Dintzner"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026-01-01T08:00:00Z","date_published":"2026-01-01T08:00:00Z","updated_at":"2026-07-24T01:38:43Z","subjects":["Cancer Biology","Medicinal and Pharmaceutical Chemistry","Oncology","Other Pharmacy and Pharmaceutical Sciences","Pharmaceutics and Drug Design"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.chapman.edu/pharmaceutical_sciences_dissertations/43","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Kamaljit Kaur","Jennifer Totonchy","Hamidreza Montazeri Aliabadi","Madeline Dintzner"]},{"key":"dc:creator","label":"Author","values":["Yao, Shih-Jing (Jane)"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmaceutical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Cancer Biology","Medicinal and Pharmaceutical Chemistry","Oncology","Other Pharmacy and Pharmaceutical Sciences","Pharmaceutics and Drug Design"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.chapman.edu/pharmaceutical_sciences_dissertations/43"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["A significant problem faced in oncology is the lack of chemotherapeutic agents that are tumor site-specific, resulting in reduced therapeutic efficacy and unintended infliction of harm to surrounding healthy tissues and cells that often lead to serious side effects. Current strategies being explored to circumvent this issue aim to refine delivery of chemotherapeutic agents specifically to tumor sites, which may be achieved via conjugation of these agents to biomarker-specific ligands. This forms the foundation of ligand-targeted drug delivery. Among different breast cancers, treatment of the triple-negative breast cancer (TNBC) subtype has been particularly challenging, largely due to the absence of a well-defined biomarker to exploit for targeted drug delivery. This has substantially limited the number of effective TNBC treatment options, funneling down primarily to conventional chemotherapy, the long-standing standard of care. The scope of this dissertation covers the peptide–drug conjugate (PDC) therapeutic modality. The findings herein delineate novel ligands, targets, and PDCs for effectively targeting TNBC.
"]},{"key":"dc:source","label":"Dc Source","values":["Yao, S-J. Evaluation of Peptides and Peptide–Doxorubicin Conjugates Designed and Synthesized for Targeting Triple-Negative Breast Cancer via Cell-Surface Receptors. [dissertation]. Irvine, CA: Chapman University; 2026. https://doi.org/10.36837/chapman.000716"]},{"key":"dc:title","label":"Title","values":["Evaluation of Peptides and Peptide–Doxorubicin Conjugates Designed and Synthesized for Targeting Triple-Negative Breast Cancer via Cell-Surface Receptors"]}]}],"canonical_facts":{"dc:contributor":["Kamaljit Kaur","Jennifer Totonchy","Hamidreza Montazeri Aliabadi","Madeline Dintzner"],"dc:creator":["Yao, Shih-Jing (Jane)"],"dc:description.abstract":["A significant problem faced in oncology is the lack of chemotherapeutic agents that are tumor site-specific, resulting in reduced therapeutic efficacy and unintended infliction of harm to surrounding healthy tissues and cells that often lead to serious side effects. Current strategies being explored to circumvent this issue aim to refine delivery of chemotherapeutic agents specifically to tumor sites, which may be achieved via conjugation of these agents to biomarker-specific ligands. This forms the foundation of ligand-targeted drug delivery. Among different breast cancers, treatment of the triple-negative breast cancer (TNBC) subtype has been particularly challenging, largely due to the absence of a well-defined biomarker to exploit for targeted drug delivery. This has substantially limited the number of effective TNBC treatment options, funneling down primarily to conventional chemotherapy, the long-standing standard of care. The scope of this dissertation covers the peptide–drug conjugate (PDC) therapeutic modality. The findings herein delineate novel ligands, targets, and PDCs for effectively targeting TNBC.
"],"dc:identifier":["https://digitalcommons.chapman.edu/pharmaceutical_sciences_dissertations/43"],"dc:source":["Yao, S-J. Evaluation of Peptides and Peptide–Doxorubicin Conjugates Designed and Synthesized for Targeting Triple-Negative Breast Cancer via Cell-Surface Receptors. [dissertation]. Irvine, CA: Chapman University; 2026. https://doi.org/10.36837/chapman.000716"],"dc:subject":["Cancer Biology","Medicinal and Pharmaceutical Chemistry","Oncology","Other Pharmacy and Pharmaceutical Sciences","Pharmaceutics and Drug Design"],"dc:title":["Evaluation of Peptides and Peptide–Doxorubicin Conjugates Designed and Synthesized for Targeting Triple-Negative Breast Cancer via Cell-Surface Receptors"],"thesis:degree_discipline":["Pharmaceutical Sciences"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-07-24T01:38:43Z"}